Key Details
Price
$2.42Annual Revenue
$15.18 MAnnual EPS
-$1.35Annual ROE
-20.45%Beta
0.81Events Calendar
Next earnings date:
Feb 28, 2025Recent quarterly earnings:
Nov 06, 2024Recent annual earnings:
Feb 29, 2024Next ex-dividend date:
N/ARecent ex-dividend date:
N/ANext split:
N/ARecent split:
N/AAnalyst ratings
Recent major analysts updates
Market Data
Dividend
Profitability
Efficiency
Valuation
Liquidity
Cash Flow
Institutional Ownership
SEER commits to an aggressive decarbonization and carbon credit monetization program, starting with its current MV Technology solutions and its planned biocarbon production facilities both domestic and international.
Carbon Management Program by SEER and DevvStream will be centered around biogas capture and carbon sequestration through biocarbon, or biochar, production Companies plan to leverage over 150 existing SEER-affiliate biogas installations across North America with numerous multinational utility companies, food processors, brewers, and agriculture firms as well as future large-scale projects in the US and in the Kingdom of Saudi Arabia In addition to biogas and biocarbon production, the Program will also enable the generation of carbon credits from oil field emission reductions and sequestration projects Sacramento, California--(Newsfile Corp. - December 12, 2024) - DevvStream Corp. (NASDAQ: DEVS) ("DevvStream" or the "Company"), a leading carbon credit project co-development and generation firm specializing in technology-based solutions, and Strategic Environmental & Energy Resources, Inc. ("SEER"), a leading provider of environmental services, renewable fuels, and industrial waste management solutions, today announced a Carbon Management Program (the "Program") established to quantify and monetize high-quality carbon credits derived from SEER's cutting-edge technologies and projects, with a primary focus on biogas capture. Entry into the biogas industry expands the Company into an estimated $10 billion market in the United States, forecast to surpass $15 billion by 2030.
Attributes 2,440% revenue growth to increased adoption of its Proteograph™ Product Suite and exciting discoveries made by Seer customers across multiple areas of biology and disease Attributes 2,440% revenue growth to increased adoption of its Proteograph™ Product Suite and exciting discoveries made by Seer customers across multiple areas of biology and disease
REDWOOD CITY, Calif., Nov. 08, 2024 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a life sciences company commercializing a disruptive new platform for proteomics, today announced company management will be participating in the following investor conferences:
Seer, Inc. (SEER) came out with a quarterly loss of $0.34 per share versus the Zacks Consensus Estimate of a loss of $0.29. This compares to loss of $0.33 per share a year ago.
CoLab session with PrognomiQ and Salk Institute plus multiple presentations of new data offer firsthand look at multi-omic breakthroughs powered by Seer's Proteograph™ Product Suite CoLab session with PrognomiQ and Salk Institute plus multiple presentations of new data offer firsthand look at multi-omic breakthroughs powered by Seer's Proteograph™ Product Suite
Seer's Proteograph™ Product Suite reveals new insights into Alzheimer's pathways, drives population-scale plasma analysis, and captures immune dynamics in xenotransplantation—with additional breakthrough research from collaborators advancing proteomic discovery at scale Seer's Proteograph™ Product Suite reveals new insights into Alzheimer's pathways, drives population-scale plasma analysis, and captures immune dynamics in xenotransplantation—with additional breakthrough research from collaborators advancing proteomic discovery at scale
REDWOOD CITY, Calif., Aug. 22, 2024 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, today announced that the company will be participating in the upcoming Morgan Stanley 22nd Annual Global Healthcare Conference in New York, NY.
REDWOOD CITY, Calif., Aug. 09, 2024 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, today announced that the company will be participating in the upcoming Canaccord Genuity 44th Annual Growth Conference in Boston, MA.
Seer, Inc. (SEER) came out with a quarterly loss of $0.35 per share versus the Zacks Consensus Estimate of a loss of $0.36. This compares to loss of $0.37 per share a year ago.
FAQ
- What is the primary business of Seer?
- What is the ticker symbol for Seer?
- Does Seer pay dividends?
- What sector is Seer in?
- What industry is Seer in?
- What country is Seer based in?
- When did Seer go public?
- Is Seer in the S&P 500?
- Is Seer in the NASDAQ 100?
- Is Seer in the Dow Jones?
- When was Seer's last earnings report?
- When does Seer report earnings?
- Should I buy Seer stock now?